ADAMAS PHARMACEUTICALS,INC. (NASDAQ:ADMS) Files An 8-K Results of Operations and Financial ConditionItem 2.02Results of Operations and Financial Condition.
On August8, 2017, Adamas Pharmaceuticals,Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June30, 2017. A copy of the press release is furnished as Exhibit99.1 to this report.
The information in this Item 2.02 and in the press release furnished as Exhibit99.1 to this current report shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Sectionor Sections 11 and 12(a)(2)of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release furnished as Exhibit99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
|
Item 2.02 |
Financial Statements and Exhibits. |
(d)Exhibits
|
ExhibitNo. |
Description |
|
99.1 |
Press Release dated August 8, 2017. |
Adamas Pharmaceuticals Inc ExhibitEX-99.1 2 adms991earningsreleaseq220.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results EMERYVILLE,…To view the full exhibit click here
About ADAMAS PHARMACEUTICALS,INC. (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
